regorafenib + trifluridine + tipiracil + progesterone

The drug name 'regorafenib + TAS-102-Juniper Pharmaceuticals, Inc.-preterm birth' appears to be a composite entry combining unrelated clinical programs. **Regorafenib** (Stivarga) is a multi-kinase inhibitor targeting VEGFR, TIE2, and KIT, while **TAS-102** (Lonsurf) is a combination of the cytotoxic thymidine analog trifluridine and the thymidine phosphorylase inhibitor tipiracil. Both are primarily indicated for metastatic colorectal cancer and have been investigated in combination for refractory disease. In contrast, the context provided refers to **Prochieve** (8% progesterone vaginal gel), a hormonal therapy developed by **Juniper Pharmaceuticals** (formerly Columbia Laboratories) for the prevention of **preterm birth** in women with a short cervix. Prochieve was evaluated in the Phase 3 **PREGNANT trial**, which failed to meet its primary endpoint of reducing preterm birth risk before 32 weeks of gestation in 2012. There is no known clinical or biological rationale for a combination of regorafenib, TAS-102, and progesterone for the indication of preterm birth.

Brand names

StivargaLonsurfProchieve

Other names

regorafenib + TAS-102-Juniper Pharmaceuticals, Inc.-preterm birthprogesterone vaginal gel